Evaluation of T-Type Calcium Channel Blockers against Human Pancreatic MIA PaCa-2 Carcinoma Xenografts 


Vol. 34,  No. 2, pp. 482-488, Feb.  2013
10.5012/bkcs.2013.34.2.482


PDF
  Tumbnail

  Abstract

Two piperazine-containing 3,4-dihyroquinazolines (BK10007S/8S) have been synthesized, based on our previous work on the synthesis and antitumoral activity of 3,4-dihyroquinazolines. After evaluating them for T-type calcium channel blocking effect and in vitro anti-cancer effect, they were profiled for acute and repeat dose toxicity (40 mg/kg, 2 weeks) to BALB/c mice. BK10007S/8S were further in vivo evaluated against human pancreatic MIA PaCa-2 carcinoma in BALB/cnu/nu nude mice, which exhibited 54 and 61% tumor growth inhibition through 57-day oral administration of 2 mg/kg of body weight, respectively.

  Statistics
Cumulative Counts from November, 2022
Multiple requests among the same browser session are counted as one view. If you mouse over a chart, the values of data points will be shown.


  Cite this article

[IEEE Style]

J. Y. Park, H. W. Choi, D. L. Choi, S. J. Jang, J. H. Kim, J. H. Lee, D. J. Choo, J. Kim, K. Lee, J. Y. Lee, "Evaluation of T-Type Calcium Channel Blockers against Human Pancreatic MIA PaCa-2 Carcinoma Xenografts," Bulletin of the Korean Chemical Society, vol. 34, no. 2, pp. 482-488, 2013. DOI: 10.5012/bkcs.2013.34.2.482.

[ACM Style]

Jin Yeong Park, Heung Woo Choi, Doo Li Choi, Sun Jeong Jang, Je Hak Kim, Joo Han Lee, Dong Joon Choo, Jungahn Kim, Kyung-Tae Lee, and Jae Yeol Lee. 2013. Evaluation of T-Type Calcium Channel Blockers against Human Pancreatic MIA PaCa-2 Carcinoma Xenografts. Bulletin of the Korean Chemical Society, 34, 2, (2013), 482-488. DOI: 10.5012/bkcs.2013.34.2.482.

Search
(IN TITLE, AUTHOR, ABSTRACT,KEYWORDS)

Advanced Search ▼

POPULAR KEYWORDS
(TOP 10 KEYWORDS)

Recent Publications
(LAST 3 YEARS)

ISSN(Print) 0253-2964
ISSN(Online) 1229-5949